News Releases

Jun 30, 2020
Akouos Announces Closing of Initial Public Offering
BOSTON , June 30, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing
Additional Formats
Jun 25, 2020
Akouos Announces Pricing of Initial Public Offering
BOSTON, June 25, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing
Additional Formats
Mar 03, 2020
AKOUOS CLOSES $105 MILLION SERIES B FINANCING
Akouos Closes $105 Million Series B Financing Appoints Vicki Sato, Ph.D., and Heather Preston, M.D., to Board of Directors Boston, Mass. – March 3, 2020   –  Akouos, Inc. (“Akouos”), a precision genetic medicine company developing potential gene therapies to restore, improve or preserve hearing,
Additional Formats
Jan 09, 2020
AKOUOS ANNOUNCES SENIOR LEADERSHIP TEAM APPOINTMENTS
Boston, Mass. – January 9, 2020  – Akouos, a precision genetic medicine company developing potential gene therapies to restore and preserve hearing, today announced two key senior leadership appointments. Morgan Molloy joins the team as chief corporate development officer, and Karoline Shair,
Additional Formats